The accelerated NOVA-2 readout to H1 2027 is the primary catalyst — successful Phase 3 data would de-risk LB-102 and support an NDA filing. The $150M private placement removes near-term financing overhang and funds pipeline expansion. Monitor enrollment updates and any pre-NDA meeting announcements for incremental catalysts.
Price Chart
Executive Summary
LB Pharmaceuticals reported Q2 2026 financial results, with net loss of $51.6M ($1.71/share) vs $4.9M ($13.58/share) a year ago, reflecting heavy R&D investment in Phase 3 NOVA-2 and Phase 2 ILLUMINATE-1 trials. The key catalyst is the accelerated NOVA-2 topline readout to H1 2027 (from H2 2027) and a $150M July private placement extending cash runway beyond Q2 2029, supporting pipeline expansion into new indications.
Key Financial Metrics
Key Facts
- Accelerated NOVA-2 Phase 3 topline data to H1 2027 (from prior H2 2027 guidance)
- Completed $150M private placement in July 2026 for pipeline expansion
- Cash $327.8M at June 30, 2026, plus $150M July proceeds; runway beyond Q2 2029
- Net loss $51.6M in Q2 2026 vs $4.9M in Q2 2025, driven by $44.1M R&D spend
- Pre-NDA meeting with FDA planned for H2 2027 after NOVA-2 readout
- Phase 2 ILLUMINATE-1 (bipolar depression) topline expected Q1 2028
- Phase 2 MDD trial initiation expected early 2027, data H1 2029
Financial Impact
Net loss of $51.6M in Q2 2026 vs $4.9M in Q2 2025; cash $327.8M at June 30 plus $150M July placement; no revenue reported
Risk Factors
- Phase 3 NOVA-2 trial failure would severely impair LB-102's value proposition
- Dilution from $150M private placement and potential future offerings
- Pre-revenue biotech with no approved products; regulatory and clinical execution risk
- Competition from existing antipsychotics and other late-stage candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-343479 |
| Document: d303033d8k.htm | 0001193125-26-343479 |
| Document: 0001193125-26-343479-index-headers.html | 0001193125-26-343479 |
| Document: 0001193125-26-343479-index.html | 0001193125-26-343479 |
| Document: 0001193125-26-343479.txt | 0001193125-26-343479 |
| 8-K Data (Synthetic) | 0001193125-26-343479 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G/A | $34.79 | awaiting T+60 | — | $38.73 (+11.33%) |
Oct 6, 2026 20d ago | EFFECT | $34.26 | awaiting T+60 | — | $38.73 (−13.05%) |
Sep 15, 2026 5w ago | 8-K | $43.04 | awaiting T+60 | — | $38.73 (−10.01%) |
Sep 3, 2026 7w ago | 8-K | $47.52 | awaiting T+60 | — | $38.73 (−18.50%) |
Aug 11, 2026 10w ago | 8-K | $45.33 | awaiting T+60 | — | $38.73 (−14.56%) |
Aug 11, 2026 10w ago | Press Release | $45.33 | awaiting T+60 | — | $38.73 (−14.56%) |
Jul 29, 2026 12w ago | 8-K | $39.00 $39.42 | ▲ +1.08% | ▼ −3.65% | $38.73 (−0.69%) |
Jul 22, 2026 13w ago | 8-K | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $38.73 (+8.06%) |
Jul 22, 2026 13w ago | Press Release | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $38.73 (+8.06%) |
Jun 10, 2026 19w ago | 8-K | $28.54 | awaiting T+60 | — | $38.73 (+35.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers